Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

2026-02-14 - 13:40

SUZHOU, China, Feb. 14, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and